Future Fields has raised USD 11.2 million in funding from venture capitalists and government contracts, including Bee Partners, Toyota Ventures, Builders VC, and AgFunder, and others.
The company will use the funds to open a production facility and scale its team with a focus on creating biomolecules using its EntoEngine™ technology. The technology uses fruit flies to create key biomolecules for various industries, including cultured meat, medical research, and biopharmaceuticals, which are faster and more scalable than traditional bioreactors.
Founded in 2018, Future Fields claims to provide a more sustainable and cost-effective way to produce recombinant proteins for cell culture, with a smaller greenhouse gas footprint than existing bioreactor technology. The company's technology is said to quickly add more supply with minimal investment and have better control over the quality of its product, making it an attractive solution to meet the growing demand for bioreactors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.